Drug intelligence / Profile preview

tivozanib + temsirolimus

Development stage
Phase 1
Lead developer
AVEO Oncology
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Tivozanib + temsirolimus is a combination therapy investigated for the treatment of advanced renal cell carcinoma (RCC). Tivozanib is a potent and selective small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, thereby inhibiting tumor angiogenesis and growth. Temsirolimus is an mTOR inhibitor that binds to FKBP12 to inhibit the mammalian target of rapamycin pathway, resulting in cell cycle arrest at G1 phase and reduced synthesis of proteins involved in proliferation, survival, and angiogenesis. The combination has demonstrated acceptable tolerability with manageable toxicity in early-phase clinical studies for RCC[2][3][5].

Brand names
Fotivda (tivozanib)Torisel (temsirolimus)
Other names
tivozanib + temsirolimus
02

Targets

VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on tivozanib + temsirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tivozanib + temsirolimus.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call